Sarepta Therapeutics Outlines 2026 Priorities on Strong Cash Position NTIP Q1 2026 Earnings Revenue Absent EPS Negative as Licensing Activity Remains Subdued Growing Global LNG Demand May Expand Strategic Focus for Ksi Lisims Project